Author
Listed:
- Ni Li
(The Institute of Cancer Research
The Institute of Cancer Research)
- David C. Johnson
(The Institute of Cancer Research)
- Niels Weinhold
(Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
University of Heidelberg)
- James B. Studd
(The Institute of Cancer Research)
- Giulia Orlando
(The Institute of Cancer Research)
- Fabio Mirabella
(The Institute of Cancer Research)
- Jonathan S. Mitchell
(The Institute of Cancer Research)
- Tobias Meissner
(Avera Cancer Institute)
- Martin Kaiser
(The Institute of Cancer Research)
- Hartmut Goldschmidt
(University of Heidelberg
National Centre of Tumor Diseases)
- Kari Hemminki
(German Cancer Research Center
Center for Primary Health Care Research, Lund University)
- Gareth J. Morgan
(Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences)
- Richard S. Houlston
(The Institute of Cancer Research
The Institute of Cancer Research)
Abstract
Genome-wide association studies have identified several risk loci for multiple myeloma (MM); however, the mechanisms by which they influence MM are unknown. Here by using genetic association data and functional characterization, we demonstrate that rs4487645 G>T, the most highly associated variant (P = 5.30 × 10−25), resides in an enhancer element 47 kb upstream of the transcription start site of c-Myc-interacting CDCA7L. The G-risk allele, associated with increased CDCA7L expression (P=1.95 × 10−36), increases IRF4 binding and the enhancer interacts with the CDCA7L promoter. We show that suppression of CDCA7L limits MM proliferation through apoptosis, and increased CDCA7L expression is associated with adverse patient survival. These findings implicate IRF4-mediated CDCA7L expression in MM biology and indicate how germline variation might confer susceptibility to MM.
Suggested Citation
Ni Li & David C. Johnson & Niels Weinhold & James B. Studd & Giulia Orlando & Fabio Mirabella & Jonathan S. Mitchell & Tobias Meissner & Martin Kaiser & Hartmut Goldschmidt & Kari Hemminki & Gareth J., 2016.
"Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression,"
Nature Communications, Nature, vol. 7(1), pages 1-9, December.
Handle:
RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms13656
DOI: 10.1038/ncomms13656
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms13656. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.